A nationwide, prospective, multicenter randomized controlled clinical trial to evaluate the therapeutic effects of the fiber tract-based artificial intelligence (AI) Robot Guiding System on the perioperative and long-term recovery of patients with moderate-volume basal ganglion hemorrhage.
Age ≥18 years at randomization
Hypertensive basal ganglia hemorrhage confirmed by CT/CTA
Hematoma volume 15-30 mL (excluding 30 mL)
Functional impairment (aphasia, hemiparesis with strength ≤3, or NIHSS ≥15)
Hematoma involving the thalamus, midbrain, or other areas
Radiologically diagnosed cerebrovascular abnormalities, as well as ischemic infarction converting to intracerebral hemorrhage, or recent (within 1 year) recurrence of intracerebral hemorrhage
Signs of impending brain herniation, such as midline shift >1 cm or changes in the ipsilateral pupil;
Any irreversible coagulopathy disorders or known coagulation system disease; platelet count <100,000; INR >1.4; use of anticoagulants within 7 days prior to this hemorrhage;
Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead sponsor
Huashan Hospital
Collaborator
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Collaborator
China-Japan Friendship Hospital
Collaborator